A Phase I/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of ZN-e4 (KP-673) in Patients with Advanced Non-Small Cell Lung Cancer with activating Epidermal Growth Factor Receptor (EGFR) mutations
The cells in our bodies are constantly dividing to create new cells and new tissue. This division requires the cell to first replicate our DNA and RNA. Replication must be done exactly. There is no room for error. Yet errors occur. Most of the time, cells that contain damaged DNA are not allowed to replicate and they die without causing us any problems. However, this is not always the case.
If you copy a letter, then make another copy from the copy, and another, and another, it’s not long until you can no longer read the letter. If cells make damaged copies of DNA, then copy those damaged DNA strands again and again, these cells no longer function properly and make you sick. This is called Cancer.
Understanding the genetics of cancer is crucial in the development of new drugs. These new drugs need to be compared to what we currently use to see if they are better at fighting cancer. Clinical research studies bring these innovative new treatments to you allowing access to advanced medicines not yet on the market. One such new drug has been brought to us by Zeno Pharmaceuticals.
ZN-e4 is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC) that has EGFR (epidermal growth factor receptor) mutations. Mutation or damage to a certain gene causes EGFR to remain stuck in the “on” position. This results in abnormal cell growth which is what cancer is. ZN-e4 inhibits EGFR so the cancer cannot grow.
If you are interested in more information on this study, please contact us. Refer to the Zeno ZN-e4 study. You can also find information on this study by going to clinicaltrials.gov website and searching for NCT03446417.